Alzheimer disease therapy--moving from amyloid-β to tau

Area of Science:

• Neuroscience
• Neurology
• Pathology

Background:

• Current Alzheimer disease (AD) treatments primarily target amyloid-beta (Aβ) reduction in the brain.
• Despite some success in lowering Aβ levels, these therapies have not yielded clinically significant improvements in patients.
• The amyloid cascade hypothesis, central to AD pathogenesis, may not fully account for the disease's clinical progression.

Purpose of the Study:

• To critically analyze the reasons behind the failure of Aβ-targeted therapies for AD.
• To discuss the limitations of the current amyloid cascade hypothesis in explaining AD.
• To propose tau pathology as a more promising therapeutic target for AD.

Main Methods:

• Review of clinical trial data for Aβ-directed AD therapies.
• Analysis of existing literature on AD pathogenesis and cognitive decline correlations.
• Examination of preclinical data from tau-targeting immunization studies in animal models.

Main Results:

• Aβ-targeting treatments have not demonstrated clinically meaningful benefits.
• Amyloid deposition shows weak correlation with cognitive decline, unlike tau pathology and neurodegeneration.
• Animal studies show reduction of intracellular tau and phosphorylated tau improves cognitive performance.

Conclusions:

• Aβ-directed therapies have largely failed to produce clinically meaningful results in Alzheimer disease.
• Tau pathology, including hyperphosphorylated tau and neurofibrillary tangles, is more closely associated with cognitive deficits than amyloid plaques.
• Targeting tau pathology, potentially through vaccines, represents a promising alternative therapeutic strategy for Alzheimer disease.